The product Xolair has a history that goes back several decades. It was originally approved in 2003 for the treatment of moderate to severe asthma. The drug was subsequently granted marketing ...

Xolair (omalizumab) , an injected drug approved two decades ago for asthma, has now been cleared ... with just 6 percent of people taking placebo injections, the FDA said. Results were similar ...

It added that the most common side effects of Xolair observed included injection site reactions and ... of moderate to severe persistent allergic asthma in certain patients. It was also approved ...

The FDA has approved a new prefilled syringe formulation for Roche’s asthma drug Xolair, as the Swiss company ... in the US and EU as a subcutaneous injection lasting a few minutes, instead ...

Genentech’s Xolair (omalizumab) has been approved in the US for moderate to severe persistent asthma in children. The Roche unit said the label extension applies to children aged six to 11 years ...